

PharmaInformatic

- Expert systems for pharmaceutical research -


PharmaInformatic provides cheminformatic services and predictive tools to improve drug discovery and preclinical compound selection. Specialised expert systems in different therapeutic areas help to discover and validate hits, followed by selection and prioritisation of suitable compounds.

The average cost of developing a new drug is about 900 million US dollars and the whole process can take more than 12 years. Only one molecule out of millions of possible substances will come up to expectations and generate profit. Our expert systems identify promising drug candidates at the earliest stage. This reduces failure rates and saves time and money.

Our platform technology contains millions of substances together with experimental data and thousands of 3D-models of biomolecules. Proprietary methods based on cheminformatics and bioinformatics allow the prediction of biological activity of a substance and its pharmacological properties.



MolScore-Drugs helps to identify and prioritise promising drug candidates with the maximum possibility of success in human trials. The expert system prioritises drug candidates in multiple therapeutic areas.



MolScore-Antibiotics detects antibacterial drug candidates. The expert system recognises structural patterns of every type of antibiotics, even new antibiotic substances with unknown mechanism of action which are now in clinical trials.



MolScore-Antivirals detects antiviral drug candidates. The expert system combines different strategies of drug research, so that structural patterns of virus-specific and target-specific inhibitors will be recognised.

PharmaInformatic also develops **tailor-made expert systems** for the specific needs of our customers. These expert systems help to discover drug candidates in customer-specific therapeutic areas. MolScore-products can be used in combination with other predictive tools derived from PharmaInformatic's in-house **ADME/Tox-database**. This unique pharmacokinetic data collection currently contains more than 16.000 data entries. A combination of multiple models identifies potential risks in order to reduce clinical failures and prioritise compounds with the maximum possibility of success in human trials.

PharmaInformatic was founded in 2004 by Dr Wolfgang Boomgaarden. He has developed virtual screening and drug design products, which have been successfully used for a number of years in the pharmaceutical world. Before he founded the company, he worked as a professor in bioinformatics at the University of Applied Science in Emden, Germany. PharmaInformatic's technology is continually being developed by an interdisciplinary network of biologists, medicinal chemists and bio-IT professionals.

Contact: PharmaInformatic, Friesenstr. 36, 26721 Emden, Germany, www.pharmainformatic.com
Dr Wolfgang Boomgaarden (Tel:+49-4921-993360), email: mail@pharmainformatic.com